

October 1, 2026

SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director,
President and Chief Executive Officer
Keiichi Fujiwara
Interim CFO
TEL: +81-3-5472-1125

**Notice Regarding the Monthly Exercise Status of the 70th and 71st Stock Acquisition Rights
(with Exercise Price Adjustment Clause) Issued through Third-Party Allotment**

SymBio Pharmaceuticals Limited (the “Company”) hereby announces the monthly exercise status for September 2026 of the 70th Stock Acquisition Rights, which were allotted to EVO FUND and issued on September 2, 2026 (the 70th Stock Acquisition Rights and the 71st Stock Acquisition Rights are collectively or individually referred to as the “Stock Acquisition Rights”).

The exercise price of the 71st Stock Acquisition Rights issued to EVO FUND on September 2, 2026 has been revised in line with the exercise price of the 70th Stock Acquisition Rights described in “6. Exercise Status in the Relevant Month” below. However, under the purchase agreement with EVO FUND, the 71st Stock Acquisition Rights are structured so that they cannot be exercised until the Company gives an instruction to commence exercise. Therefore, the Company has omitted the disclosure of the monthly exercise status of the 71st Stock Acquisition Rights.

1.	Name of Stock Acquisition Rights	SymBio Pharmaceuticals Limited’s 70th Stock Acquisition Rights
2.	Number of Shares Delivered in the Relevant Month	4,300,000 shares
3.	Number of Stock Acquisition Rights Exercised in the Relevant Month, and Ratio of Exercised to Total Issued Stock Acquisition Rights	43,000 rights (Ratio to total number of Stock Acquisition Rights issued 480,000: 9.0%)
4.	Number of Unexercised Stock Acquisition Rights as of September 2, 2026	480,000 rights
5.	Number of Unexercised Stock Acquisition Rights as of the End of the Relevant Month	437,000 rights

* The ratio of exercised to total issued Stock Acquisition Rights is rounded to one decimal place.

6. Exercise Status in the Relevant Month

SymBio Pharmaceuticals Limited’s 70th Stock Acquisition Rights

Exercise Date	Number of Shares Delivered		Exercise Price (Yen)	Number of Stock Acquisition Rights Exercised (Rights)
	Newly Issued Shares	Transferred Treasury Shares		
September 3 (Thu)	-	-	71	-
September 4 (Fri)	-	-	61	-
September 7 (Mon)	90,000	-	61	900
September 8 (Tue)	500,000	-	60	5,000
September 9 (Wed)	-	-	60	-

September 10 (Thu)	390,000	-	59	3,900
September 11 (Fri)	260,000	-	58	2,600
September 14 (Mon)	270,000	-	57	2,700
September 15 (Tue)	270,000	-	56	2,700
September 16 (Wed)	100,000	-	56	1,000
September 17 (Thu)	950,000	-	53	9,500
September 18 (Fri)	-	-	55	-
September 24 (Thu)	150,000	-	55	1,500
September 25 (Fri)	70,000	-	56	700
September 28 (Mon)	-	-	58	-
September 29 (Tue)	50,000	-	57	500
September 30 (Wed)	1,200,000	-	55	12,000

* Number of shares issued as of September 2, 2026: 80,247,210 shares (including 91,319 treasury shares)

7. Status of Exercise Restrictions (Status of Compliance with Exercise Restrictions under Article 434 of the Listing Regulations)

(i) Total Number of Shares Delivered (All Series Combined)	(ii) Number of Listed Shares as of Payment Date of Issuance	(iii) Exercise Ratio Subject to Exercise Restrictions ((i) / (ii))
4,300,000 shares	80,247,210 shares	5.4%

* The exercise ratio subject to exercise restrictions is rounded to one decimal place.

* The purchase agreement for the Stock Acquisition Rights entered into between the Company and EVO FUND provides that, pursuant to Article 436, Paragraph 5, Item 4 of the Enforcement Rules for the Securities Listing Regulations established by the Tokyo Stock Exchange, the prohibition on Excess Exercise shall not apply if the exercise price is equal to or higher than the closing price on August 17, 2026, the date of the resolution for issuance.

For details concerning the Stock Acquisition Rights, please refer to the “Notice Regarding the Execution of an Unsecured Bond Facility Agreement, the Issuance of the 2nd Unsecured Straight Bonds (Private Placement), the Issuance of the 70th and 71st Stock Acquisition Rights (with Exercise Price Adjustment Clauses) through Third-Party Allotment, the Execution of a Purchase Agreement for the Stock Acquisition Rights (Commit Issue), and the Acquisition and Cancellation of the 58th, 66th, and 67th Stock Acquisition Rights” announced on August 17, 2026.